Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
DSCI [NASD]
Derma Sciences Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own1.50% Shs Outstand25.14M Perf Week-9.59%
Market Cap237.07M Forward P/E- EPS next Y-1.05 Insider Trans-42.08% Shs Float23.87M Perf Month-27.35%
Income-24.00M PEG- EPS next Q-0.32 Inst Own54.50% Short Float4.04% Perf Quarter-22.70%
Sales79.70M P/S2.97 EPS this Y-44.30% Inst Trans3.07% Short Ratio4.58 Perf Half Y-23.15%
Book/sh4.46 P/B2.11 EPS next Y35.60% ROA-25.10% Target Price19.00 Perf Year-20.08%
Cash/sh0.88 P/C10.78 EPS next 5Y- ROE-28.40% 52W Range9.41 - 15.51 Perf YTD-12.85%
Dividend- P/FCF- EPS past 5Y-11.30% ROI-31.40% 52W High-39.20% Beta1.32
Dividend %- Quick Ratio3.50 Sales past 5Y9.70% Gross Margin36.90% 52W Low0.21% ATR0.50
Employees258 Current Ratio5.20 Sales Q/Q3.00% Oper. Margin-30.10% RSI (14)15.05 Volatility4.63% 4.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.80% Profit Margin-29.90% Rel Volume0.76 Prev Close9.66
ShortableYes LT Debt/Eq0.00 EarningsMay 12 Payout- Avg Volume210.78K Price9.43
Recom1.80 SMA20-17.97% SMA50-26.68% SMA200-25.56% Volume160,127 Change-2.38%
17-Mar-14Reiterated Oppenheimer Outperform $19 → $21
06-Jul-11Initiated Oppenheimer Outperform $21
09-Feb-11Reiterated Rodman & Renshaw Mkt Outperform $13 → $25
14-May-10Initiated Rodman & Renshaw Mkt Outperform $13
27-Mar-14 04:36PM  DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
19-Mar-14 01:04PM  DERMA SCIENCES, INC. Financials EDGAR Online Financials
14-Mar-14 04:34PM  Derma Sciences' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:34AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:30AM  Derma Sciences Reports Fourth Quarter Financial Results, Provides Commercial Update Including Sales Force Expansion and Progress in Launching New Placental-Derived Tissue Products Business Wire
07:30AM  Derma Sciences Reports Fourth Quarter Financial Results, Provides Commercial Update Including Sales Force Expansion and Progress in Launching New Placental-Derived Tissue Products
07:07AM  Q4 2013 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
13-Mar-14 05:30PM  DERMA SCIENCES, INC. Files SEC form 10-K, Annual Report EDGAR Online
10-Mar-14 07:30AM  Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 14th Business Wire
07:30AM  Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 14th
04-Mar-14 07:30AM  Derma Sciences to Present at the 26th Annual ROTH Conference Business Wire
07:30AM  Derma Sciences to Present at the 26th Annual ROTH Conference
28-Feb-14 10:05AM  Evaluate Biotech Stocks With Cynicism: Debjit Chattopadhyay at Seeking Alpha
19-Feb-14 01:17PM  Derma Sciences: A Not Well Followed Growth Company With Solutions For Diabetic Foot Ulcers at Seeking Alpha
01:17PM  Derma Sciences: A Not Well Followed Growth Company With Solutions For Diabetic Foot Ulcers
05-Feb-14 03:30PM  3 Micro-Cap Stocks With Triple-Digit Upside StreetAuthority Network
31-Jan-14 06:34AM  Can Derma Sciences (DSCI) Continue to Rise? Zacks
06:34AM  Can Derma Sciences (DSCI) Continue to Rise?
30-Jan-14 05:43AM  Derma Sciences (DSCI) Jumps: Stock Rises 6.2% Zacks
05:43AM  Derma Sciences (DSCI) Jumps: Stock Rises 6.2%
29-Jan-14 10:17AM  Derma Sciences Closes $86 Million Underwritten Public Offering of Common Stock, Including Full Over-Allotment Business Wire +6.15%
10:17AM  Derma Sciences Closes $86 Million Underwritten Public Offering of Common Stock, Including Full Over-Allotment
27-Jan-14 05:30PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit EDGAR Online
05:30PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
24-Jan-14 09:00AM  Derma Sciences Announces Pricing of Underwritten Public Offering of Common Stock Business Wire
09:00AM  Derma Sciences Announces Pricing of Underwritten Public Offering of Common Stock
23-Jan-14 04:01PM  Derma Sciences Announces Commencement of Public Offering of Common Stock Business Wire
04:01PM  Derma Sciences Announces Commencement of Public Offering of Common Stock
21-Jan-14 04:27PM  DERMA SCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
04:27PM  DERMA SCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
17-Jan-14 05:13PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financ EDGAR Online
05:13PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financ
16-Jan-14 07:00AM  Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials Business Wire
07:00AM  Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials
14-Jan-14 10:47AM  Stocks: Insiders Buy at Opko Health and DDR; Ironwood Pharmaceuticals Sees a Sale at Minyanville
09:18AM  Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products Business Wire
09:18AM  Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products
20-Dec-13 06:03PM  Nasdaq stocks posting largest volume increases AP
19-Dec-13 06:03PM  Nasdaq stocks posting largest volume increases AP
04-Dec-13 09:00AM  Derma Sciences to Present at the Oppenheimer & Co. Inc. 24th Annual Healthcare Conference Business Wire
09:00AM  Derma Sciences to Present at the Oppenheimer & Co. Inc. 24th Annual Healthcare Conference
25-Nov-13 10:45AM  INSERTING and REPLACING Derma Sciences to Participate in the 25th Annual Piper Jaffray Healthcare Conference Business Wire
10:45AM  INSERTING and REPLACING Derma Sciences to Participate in the 25th Annual Piper Jaffray Healthcare Conference
09:00AM  Derma Sciences to Participate in the 25th Annual Piper Jaffray Healthcare Conference Business Wire
20-Nov-13 01:04PM  DERMA SCIENCES, INC. Financials EDGAR Online Financials
01:04PM  DERMA SCIENCES, INC. Financials
14-Nov-13 05:55AM  Derma Sciences assumed with an Outperform at Oppenheimer at theflyonthewall.com
05:55AM  Derma Sciences assumed with an Outperform at Oppenheimer
13-Nov-13 03:09PM  Derma Sciences' CEO Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
03:09PM  Derma Sciences' CEO Discusses Q3 2013 Results - Earnings Call Transcript
11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today
10:50AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:35AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:30AM  Derma Sciences Reports Third Quarter Financial Results Business Wire
07:30AM  Derma Sciences Reports Third Quarter Financial Results
07:07AM  Q3 2013 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
07:07AM  Q3 2013 Derma Sciences, Inc. Earnings Release - Before Market Open
12-Nov-13 04:29PM  DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
04:29PM  DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report
03:17PM  New Drug Could Transform Derma Sciences, CEO Says at Barrons.com
03:17PM  New Drug Could Transform Derma Sciences, CEO Says
08:30AM  Derma Sciences to Participate in the Canaccord Genuity Medical Technology & Diagnostics Forum Business Wire
06-Nov-13 10:39AM  Derma Sciences to Hold Third Quarter Financial Results Conference Call on November 13th Business Wire
02-Oct-13 01:38PM  Derma Sciences to Showcase MEDIHONEY® and TCC-EZ® at Novation Innovative Technology Expo Business Wire
05-Sep-13 04:07PM  DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
04-Sep-13 08:01AM  InPlay: Derma Sciences Acquires 7.3% of Comvita to Support Vertical Integration of Key Component in MEDIHONEY Products Briefing.com
08:01AM  InPlay: Derma Sciences Acquires 7.3% of Comvita to Support Vertical Integration of Key Component in MEDIHONEY Products Briefing.com
08:00AM  Derma Sciences Acquires 7.3% of Comvita to Support Vertical Integration of Key Component in MEDIHONEY® Products Business Wire
27-Aug-13 03:08PM  The Changing Landscape in Chronic Diabetic Foot Ulcers at Motley Fool
20-Aug-13 01:04PM  DERMA SCIENCES, INC. Financials EDGAR Online Financials +5.48%
18-Aug-13 01:51PM  Sanuwave May Be Able To Satisfy Investor Appetite For A Diabetic Foot Ulcer Treatment at Seeking Alpha
13-Aug-13 11:13AM  An Incredibly Asymmetric Risk/Reward Ratio For Sanuwave Foreshadows Huge Upside at Seeking Alpha
08:05AM  Company News for August 13, 2013 Zacks
12-Aug-13 06:19PM  Derma Sciences' CEO Discusses Q2 2013 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
08:37AM  DERMA SCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
07:35AM  Derma Sciences, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:30AM  Derma Sciences Reports Second Quarter Financial Results Business Wire
07:15AM  Derma Sciences Ships First MEDIHONEY over-the-counter Product to Leading U.S. Pharmacy Chain Business Wire
07:07AM  Q2 2013 Derma Sciences, Inc. Earnings Release - Before Market Open CCBN
05-Aug-13 08:00AM  Derma Sciences to Present at the Canaccord Genuity 33rd Annual Growth Conference Business Wire
02-Aug-13 09:15AM  Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 12th Business Wire
25-Jul-13 06:02PM  Nasdaq stocks posting largest volume increases AP
07:06AM  InPlay: Derma Sciences CEO highlights rapid growth of MEDIHONEY products in presentation at Comvita annual meeting Briefing.com
07:00AM  Derma Sciences CEO Highlights Rapid Growth of MEDIHONEY Products in Presentation at Comvita Annual Meeting Business Wire
24-Jul-13 06:05PM  Nasdaq stocks posting largest volume increases AP +7.22%
19-Jul-13 01:02AM  How Fast Is the Cash at Derma Sciences? at Motley Fool
15-Jul-13 01:38PM  Diversified Equity Income Investing: a Wall Street Transcript Interview with Shaun Hong, Managing Director and Equity Portfolio Manager/Research Analyst for Jennison Associates Wall Street Transcript
10-Jul-13 01:59AM  Why Derma Sciences's Earnings May Not Be So Hot at Motley Fool
13-Jun-13 12:17AM  Derma Sciences' CEO Hosts Analyst Day Conference (Transcript) at Seeking Alpha
12-Jun-13 03:56PM  Sanuwave: DermaPACE Could Be Very Competitive In $2B Diabetic Foot Ulcer Market at Seeking Alpha
07:30AM  Published Research Concludes Total Contact Casting is More Effective in Healing Diabetic Foot Ulcers Than Other Standards of Care Business Wire
07:25AM  Derma Sciences reports positive results from Phase 1 diabetic foot ulcer study theflyonthewall.com
07:17AM  InPlay: Derma Sciences reports results from DSC127 pharmacokinetic study; DSC127 was not detected in any subject's serum samples at any time point Briefing.com
07:15AM  Derma Sciences Reports Results from DSC127 Pharmacokinetic Study Business Wire
07-Jun-13 11:14AM  Derma Sciences to Webcast June 12 Analyst Day Business Wire
01:04AM  Did Derma Sciences Squander Its Latest Sales Increase? at Motley Fool
30-May-13 05:28PM  InPlay: Derma Sciences: Raging Capital Management discloses 9.9% passive stake in 13G filing Briefing.com
Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. The company offers Medihoney dressings for managing non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; TCC-EZ total contact cast system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair and regeneration; and AMNIOMATRIX, which is used as a wound covering in the treatment of localized tissue defects. It also provides Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; Bioguard dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. In addition, the company offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Further, it develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers and preclinical testing for scar reduction. The company sells its products to various health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians' offices, nursing homes, hospitals, and clinics through direct sales and manufacturers' representatives, independent distributors, and retail channels primarily in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLE ROBERT CSee RemarksFeb 14Option Exercise12.403,12538,75062,938Feb 19 05:40 PM
Eigner FredericExecutive VP - OperationsFeb 14Option Exercise12.403,75046,50050,300Feb 19 05:37 PM
YETTER JOHN EEVP, Finance & CFOFeb 14Option Exercise12.403,12538,75053,709Feb 19 05:35 PM
QUILTY EDWARD JPresident & CEOFeb 14Option Exercise12.406,25077,500166,043Feb 19 05:33 PM